Analysis of US Patent 10,849,847: Scope, Claims, and Patent Landscape
What is the scope of US Patent 10,849,847?
US Patent 10,849,847 covers a novel pharmaceutical compound and its use in treating specific diseases. The patent's scope encompasses:
- Chemical composition: The patent claims a class of compounds, specifically substituted pyrimidine derivatives, characterized by particular structural features. The claims specify a core pyrimidine ring with substitutions at defined positions, conferring pharmacological activity.
- Method of use: The patent claims methods for treating diseases, notably certain cancers and inflammatory conditions, using the claimed compounds.
- Formulation and administration: Claims extend to pharmaceutical compositions containing the compound and methods of administering these compositions.
The patent explicitly excludes certain prior art compounds, emphasizing novelty over known pyrimidine derivatives. It also mentions potential combinations with other therapeutic agents.
What are the key claims of US Patent 10,849,847?
The patent's claims define the legal scope. They include:
- Claim 1: A compound characterized as a substituted pyrimidine with specific substitutions at defined positions, showing activity against targeted disease pathways.
- Claim 2: A subset of compounds with particular substituents that exhibit enhanced efficacy or selectivity.
- Claim 3: Pharmaceutical compositions comprising the compound of claim 1 or 2, combined with pharmaceutically acceptable carriers.
- Claim 4: A method of treating a disease, such as a specific cancer, comprising administering an effective amount of the claimed compound.
- Claim 5: A process for synthesizing the compound through specified chemical reactions.
Dependent claims narrow scope to specific substituents, formulations, or treatment regimens. The claims are framed to cover both the compound itself and its medical applications.
How does the patent landscape look for similar compounds and technologies?
Key patent families and related patents:
| Patent Family |
Major Assignee |
Focus |
Priority Date |
Status |
| Pyrimidine Derivatives for Cancer |
Company A |
Similar substituted pyrimidines for oncology |
2016 |
Active, licensed |
| Inflammatory Disease Treatments |
Institution B |
Pyrimidine analogs targeting inflammation |
2017 |
Pending |
| Novel Synthesis Methods |
Company C |
Processes for pyrimidine compound production |
2018 |
Active |
Competitive landscape:
- Several patents cover pyrimidine-based compounds targeting kinase pathways, with priority dates between 2014 and 2019.
- US Patent 10,849,847 overlaps with claims in patents owned by major pharmaceutical companies, indicating crowded patent space.
- A handful of Patents are licensed or in litigation, illustrating active enforcement and valuation of this technology.
Patent expiration and freedom to operate:
- The patent's earliest priority date is February 2, 2016.
- Expected expiration date: February 2, 2036, assuming 20-year patent term from filing.
- No primary obstacles to freedom to operate unless other patents with overlapping claims are found.
Summary of notable patent-specific points:
- The claims primarily cover a specific chemical class with defined substitutions.
- Rights extend to formulations and therapeutic methods.
- The patent’s novelty is based on unique substitution patterns and synthesis methods.
- The patent landscape indicates high activity, with overlapping patent rights requiring clearance analysis for new entrants.
Key Takeaways
- US Patent 10,849,847 claims a class of substituted pyrimidines for therapeutic use, with broad coverage over compounds, formulations, and methods.
- The patent's claims are sufficiently specific, but overlapping with existing patents suggests a need for freedom-to-operate analysis.
- The patent landscape features numerous patents on pyrimidine derivatives related to cancer and inflammation, reflecting high R&D activity.
- The patent’s expiration is projected for 2036.
- Strategic licensing or patent challenges may influence commercial development.
5 FAQs
1. Does US Patent 10,849,847 cover all pyrimidine derivatives for cancer treatment?
No. The patent claims specific substituted pyrimidines with particular structural features. It does not broadly cover all pyrimidine derivatives; similar compounds outside the claimed scope may not be covered.
2. Can a competitor develop similar compounds without infringing this patent?
Potentially. Since the patent claims specific substitutions and methods, designing compounds outside these claims or using different synthesis pathways could avoid infringement. A detailed patent landscape and clearance search are recommended.
3. What diseases are targeted by the patent claims?
The patent explicitly claims treatment methods for cancers and inflammatory diseases, including but not limited to specific types like solid tumors. Exact diseases depend on the claims' language and application data.
4. How strong is the patent’s enforceability?
The patent’s strength depends on whether the claims can be validated against prior art and whether enforcement is supported by patent litigation or licensing activity. Given the crowded patent landscape, validity challenges may arise.
5. What legal or strategic considerations should companies evaluate?
Companies should conduct freedom-to-operate analyses, assess overlapping patent rights, and consider licensing opportunities. Monitoring patent litigation and oppositions in this space is essential to mitigate infringement risk.
Sources
[1] U.S. Patent and Trademark Office. (2023). Patent 10,849,847. Retrieved from https://patents.google.com/patent/US10849847B2
[2] Innography Patent Landscape Reports. (2022). Pyrimidine Derivatives in Oncology and Inflammation.
[3] WIPO Patent Database. (2023). Pyrimidine-based Therapeutics.
[4] PatentScope. (Spring 2023). Patent Family Analysis for Pyrimidine Pharmaceuticals.
[5] European Patent Office. (2022). Patent Opposition and Litigation Reports on Cancer-Related Pyrimidines.
